Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences

Rhea-AI Summary

Prelude Therapeutics (Nasdaq: PRLD) announced management participation in three virtual investor conferences. Key details include:

• Barclays Global Healthcare Conference: March 10, 2021, at 8:35 a.m. ET.
• Morgan Stanley Virtual Healthcare Corporate Access Day: One-on-one meetings on March 16, 2021.
• Oppenheimer 31st Annual Healthcare Conference: March 17, 2021, at 3:50 p.m. ET.

Webcasts available on the company's website, where replays will also be accessible.

WILMINGTON, Del., March 03, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in three upcoming virtual investor conferences:

• Barclays Global Healthcare Conference
  Fireside chat at 8:35 a.m. ET on Wednesday, March 10, 2021

• Morgan Stanley Virtual Healthcare Corporate Access Day
  1x1 meetings on Tuesday, March 16, 2021

• Oppenheimer 31^st Annual Healthcare Conference
  Corporate presentation at 3:50 p.m. ET on Wednesday, March 17, 2021

A live webcast of the Barclays fireside chat and Oppenheimer presentation can be accessed under “Events & Presentations” in the Investor Section of the Company’s website, https://investors.preludetx.com/news-and-events/events-and-presentations, where a replay of the events will also be available for a limited time.

About Prelude Therapeutics

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude’s first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme (GBM). The Company’s pipeline also includes its third clinical candidate, PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed/refractory hematologic malignancies, and its two most advanced preclinical candidates, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.

Contact

Melissa Forst
Argot Partners
212.600.1902
prelude@argotpartners.com

FAQ

What are the dates for Prelude Therapeutics' virtual investor conferences?

Prelude Therapeutics will participate in three virtual investor conferences on March 10, March 16, and March 17, 2021.

How can I access the webcasts for Prelude Therapeutics' events?

Webcasts for Prelude Therapeutics' conferences can be accessed on their Investor Section of the website under 'Events & Presentations'.

What is Prelude Therapeutics focusing on in their clinical trials?

Prelude Therapeutics is focusing on innovative drug candidates targeting critical cancer cell pathways, including PRMT5 inhibitors.

What is the ticker symbol for Prelude Therapeutics?

The ticker symbol for Prelude Therapeutics is PRLD.

What are the lead product candidates of Prelude Therapeutics?

Prelude's lead product candidates include PRT543 and PRT811, which are in Phase 1 development for various cancers.